Benefits
- Can miss the window by waiting for surgery
- Improved immune response
- Can inform post surgical treatment options
Definitions
- Pathological system
- Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab.
